Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Ca...
Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
The pathologic definition of triple negative breast cancer (TNBC) relies on the absence of expression of estrogen, progesterone and HER2 receptors. However, this BC subgroup is distinguished by a wide biological, molecular and clinical heterogeneity. Among the intrinsic TNBC subtypes, the mesenchymal type is defined by the expression of genes invol...
Alternative Titles
Full title
Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7959307
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7959307
Other Identifiers
ISSN
2072-6694
E-ISSN
2072-6694
DOI
10.3390/cancers13051080
